Impact of the intratumoral microbiome of NSCLC on outcomes with immunotherapy

Stephen Liu shared on X:

“Impressive work on impact of the intratumoral microbiome of NSCLC on outcomes with immunotherapy from Dr. Arielle Elkrief in JCO. In two independent cohorts, intratumoral Escherichia was associated with longerOS (HR 0.73) with single-agent PD(L)1.”

Intratumoral Escherichia Is Associated With Improved Survival to Single-Agent Immune Checkpoint Inhibition in Patients With Advanced NSCLC

Autors: Arielle Elkrief, Meagan Montesion, Smruthy Sivakumar, Caryn Hale, Anita S. Bowman, Ayyüce Begüm Bektaş, Martina Bradic, Wenfei Kang, Eric Chan, Pooja Gogia, Katia Manova-Todorova, Douglas A. Mata, Jacklynn V. Egger, Hira Rizvi, Nicolas D. Socci, Daniel W. Kelly, Eric Rosiek, Fanli Meng, Grittney Tam, Ning Fan, Alexander Drilon, Helena A. Yu, Gregory J. Riely, Natasha Rekhtman, Álvaro Quintanal Villalonga, Snjezana Dogan, Umesh Bhanot, Mithat Gönen, Brian Loomis, Matthew D. Hellmann, Adam J. Schoenfeld, Marc Ladanyi, Charles M. Rudin, and Chad M. Vanderbilt.

Source: Stephen Liu/X

Stephen Liu is an Associate Professor of Medicine at Georgetown University, where he holds the positions of Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center. As a board-certified medical oncologist specializing in lung cancer and drug development, Dr. Liu is known for his expertise in advanced thoracic malignancies.

His research focuses on novel therapeutic agents and innovative combinations to improve treatment outcomes for patients with lung cancer. Dr. Liu has received multiple teaching awards and actively engages in post-graduate education initiatives. Furthermore, he co-hosts the official podcast of the International Association for the Study of Lung Cancer (IASLC), “Lung Cancer Considered”.